Jubilant Life gets USFDA nod for urinary incontinence drug

New Delhi : Jubilant Life Sciences has received the final approval from the US health regulator for Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence condition.

The company has "received Abbreviated New Drug Application (ANDA) final approval for Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg, the generic version of Enablex of Allergan Plc, which is used for the treatment of urinary incontinence", Jubilant Life Sciences said in a BSE filing.

Jubilant Life Sciences said it has received 6 approvals from the USFDA during the year.

As on June 30, 2016, Jubilant Life Sciences had a total of 70 ANDAs for Oral Solids filed in the US, of which 44 have been approved.